Skip to main content
ABION Inc. logo

ABION Inc. — Investor Relations & Filings

Ticker · 203400 ISIN · KR7203400007 KO Professional, scientific and technical activities
Open in API
Filings indexed 409 across all filing types
Latest filing 2022-03-10 AGM Information
Country KR South Korea
Listing KO 203400

About ABION Inc.

https://abionbio.com/en/

ABION Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative medicines, focusing on first-in-class and best-in-class therapeutics for oncology and viral diseases. The company's lead oncology asset is ABN401, a selective c-Met tyrosine kinase inhibitor (TKI) designed to treat non-small cell lung cancer (NSCLC) with MET mutations, which has shown a favorable safety profile. Another key pipeline candidate is ABN501, a novel monoclonal antibody targeting Claudin-3 for various cancers. Beyond oncology, ABION is developing ABN101, a second-generation Interferon-β formulated as a broad-spectrum anti-viral inhaler for respiratory infections. The company aims to commercialize its assets in global markets through internationally recognized clinical processes.

Recent filings

Filing Released Lang Actions
주주총회소집공고
AGM Information Classification · 98% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) issued by Abion Inc. It details the meeting date, location, agenda items (such as financial statement approval, director appointments, and remuneration limits), and provides management's report on business activities and governance. This document is a standard proxy statement/notice for an upcoming Annual General Meeting (AGM).
2022-03-10 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company 'Abion'. It outlines the date, location, and specific agenda items for the upcoming Annual General Meeting (AGM), including the approval of financial statements, election of directors, and remuneration limits. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and the matters to be voted upon. Therefore, it falls under the Proxy Solicitation & Information Statement category.
2022-03-07 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company scheduled its meeting on a date identified by the KOSDAQ Association as a 'concentrated date' for shareholder meetings. Since this is a regulatory disclosure regarding meeting logistics and compliance rather than the meeting materials themselves, the proxy statement, or the voting results, it falls under the general regulatory filing category.
2022-03-07 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Abion) disclosing a significant change in financial results (revenue or profit/loss structure change of 30% or more). This is a standard regulatory disclosure requirement in the Korean market (DART system) for listed companies to report material financial fluctuations before the final audit report is finalized. Since it provides specific financial data and reasons for the change, it fits the 'Regulatory Filings' (RNS) category as it is a mandatory disclosure of financial status. FY 2021
2022-02-10 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details changes in share ownership by major shareholders and special related parties, including stock option exercises. This corresponds to the 'Major Shareholding Notification' category.
2022-01-17 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share ownership changes of an executive (Kang Yoon Soo) at Abion Inc. This type of filing is a standard regulatory requirement for insider trading or changes in executive shareholdings, which corresponds to the 'Director's Dealing' category.
2022-01-17 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.